ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: INFO15-SA

Evaluation of ADV7103 Efficacy and Safety in Cystinuria

Session Information

  • Informational Posters - III
    November 09, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Genetic Diseases of the Kidneys


  • Guittet, Catherine, Advicenne, Nïmes, France
  • Granier, Luc andre, Advicenne, Nïmes, France
  • Bertholet-Thomas, Aurélia, Centre de Référence des Maladies Rénales Rares, Bron Cedex, France
  • Knebelmann, Bertrand, Necker Hopsital, Paris, France

BACKGROUND: Beside hyperhydration, alkaline urine pH is a cornerstone of therapeutic management of cystinuria. The presence of cystine crystals in urine (crystalluria), and more specifically high volume of crystals (Vcys > 3000 µ3/mm3) was shown to be predictive of recurrence of cystine stones (Daudon et al, 2003).

CORAL 1 is a European cystinuria clinical program including 3 studies. The main Phase IIb/III multicenter, randomized, placebo-controlled, double-blind, 4 parallel arms, dose-ranging study (B12CS) evaluates the efficacy, safety, tolerability and acceptability of repeated doses of ADV7103, after 7 days of treatment, in 60 patients with cystinuria. ADV7103 is a fixed-dose combination of potassium citrate and potassium bicarbonate formulated as prolonged release-granules. B12CS is a superiority study evaluating the efficacy of ADV7103 at 3 different doses compared to placebo. The primary objective evaluates the effect of ADV7103 compared to placebo on the percentage of urinary pH values ≥ 7.0 during repeated measures 24h after a 7-day treatment. Secondary objectives evaluate the effect and dose-response relationship of ADV7103 on urinary pH, cystine crystalluria (including Vcys) and cystinuria parameters after a 7 day-treatment.

Inclusion criteria include age 6 years and above, a confirmed cystinuria diagnosis, a well-adapted alkalizing therapy and a disease status enabling interruption of a cystine binding drug. Exclusion criteria include patients who cannot stop chelating agents, hyperkalemia > 5.0 mmol/L and eGFR < 45 mL/min/1.73 m2.

Patients below 6 years of age or urine incontinent will receive ADV7103 in an open-manner, in an exploratory sub-study (B13CS).

The first patients have been enrolled in May 2019.

A follow up study (B14CS) over 2 years will enroll patients after they finished the B12CS-B13CS study.

For more information contact


  • Sponsor Advicenne SA